Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2518-2523

  Ben Ami, Ronen ^a   Olshtain Pops, Keren ^b   Krieger, Michal ^c   Oren, Ilana ^d   Bishara, Jihad ^e   Dan, Michael ^f   Wiener Well, Yonit ^g   Weinberger, Miriam ^h   Zimhony, Oren ⁱ   Chowers, Michal ^j   Weber, Gabriel ^k   Potasman, Israel ^l   Chazan, Bibiana ^m,n   Kassis, Imad ^d   Shalit, Itamar ^e   Block, Colin ^b   Keller, Nathan ^c   Kontoyiannis, Dimitrios P ^o   Giladia, Michael ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

^e SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^f WOLFSON MEDICAL CENTER   (Israel)

^g SHAARE ZEDEK MEDICAL CENTER   (Israel)

^h ASSAF HAROFEH MEDICAL CENTER   (Israel)

ⁱ KAPLAN MEDICAL CENTER   (Israel)

^j MEIR MEDICAL CENTER   (Israel)

^k CARMEL MEDICAL CENTER   (Israel)

^l BNAI ZION MEDICAL CENTER   (Israel)

^m HAEMEK MEDICAL CENTER   (Israel)

ⁿ Rebecca Sieff Government Hospital   (Israel)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; FLUCONAZOLE; ITRACONAZOLE; MACROLIDE; METRONIDAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; VORICONAZOLE;

ACCURACY; ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CANDIDA GLABRATA; CANDIDEMIA; CHILD; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FUNGUS ISOLATION; HUMAN; INFANT; ISRAEL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTIVE VALIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CANDIDA GLABRATA; CANDIDEMIA; CANDIDIASIS; CARBAPENEMS; CLINDAMYCIN; COINFECTION; COLISTIN; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; ISRAEL; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84860188075     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05947-11     Document Type: Article

References (30)

1. Afeltra J, Verweij PE. 2003. Antifungal activity of nonantifungal drugs. Eur. J. Clin. Microbiol. Infect. Dis. 22:397- 407.
2. Beggs WH. 1982. Combined activity of ketoconazole and sulphamethoxazole against Candida albicans J. Antimicrob. Chemother. 10:539-541. (Pubitemid 13187645)
3. Chang MR, Cury AE. 1998. Amphotericin B-metronidazole combination against Candida spp. Rev. Iberoam. Micol. 15:78-80. (Pubitemid 128533464)
4. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. (Pubitemid 17055592)
5. Cole GT, Halawa AA, Anaissie EJ. 1996. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin. Infect. Dis. 22(Suppl. 2):S73-S88. (Pubitemid 26256437)
6. Cury AE, Hirschfeld MP. 1997. Interactions between amphotericin B and nitroimidazoles against Candida albicans. Mycoses 40:187-192. (Pubitemid 28018490)
7. Domer JE, Hector RF. 1987. Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans. Antimicrob. Agents Chemother. 31:691- 697.
8. Garey KW, et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31. (Pubitemid 43939072)
9. Garnacho-Montero J, et al. 2010. Risk factors for fluconazole-resistant candidemia. Antimicrob. Agents Chemother. 54:3149 -3154.
10. Gruger T, et al. 2008. Influence of fluoroquinolones on phagocytosis and killing of Candida albicans by human polymorphonuclear neutrophils. Med. Mycol. 46:675-684.
11. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
12. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. 2003. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch. Intern. Med. 163:972-978. (Pubitemid 36519743)
13. Henry KW, Cruz MC, Katiyar SK, Edlind TD. 1999. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob. Agents Chemother. 43:1968 -1974.
14. Horn DL, et al. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48:1695-1703.
15. Lee I, et al. 2009. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch. Intern. Med. 169:379-383.
16. Lehrer RI. 1971. Inhibition by sulfonamides of the candidacidal activity of human neutrophils. J. Clin. Invest. 50:2498-2505.
17. Lin MY, et al. 2005. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob. Agents Chemother. 49:4555-4560. (Pubitemid 41552584)
18. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
19. Paterson DL. 2004. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl. 4):S341-S345. (Pubitemid 38669889)
20. Pfaller MA, et al. 2004. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J. Clin. Microbiol. 42:3142-3146. (Pubitemid 38938071)
21. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
22. Pultz NJ, Stiefel U, Ghannoum M, Helfand MS, Donskey CJ. 2005. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob. Agents Chemother. 49:438-440. (Pubitemid 40065827)
23. Rosenbaum P, Rubin DB. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55.
24. Rubin DB. 1997. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. 127:757-763. (Pubitemid 27446562)
25. Sipsas NV, et al. 2009. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115:4745- 4752.
26. Trenschel R, et al. 2000. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination. Bone Marrow Transplant. 26:993-997.
27. Wingard JR, et al. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.
28. Zaoutis TE, et al. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41:1232-1239. (Pubitemid 41532664)
29. Zaoutis TE, et al. 2010. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin. Infect. Dis. 51:e38-e45.
30. Zhai B, et al. 2010. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother. 65:931-938.